4.235
price down icon0.59%   -0.025
 
loading
Schlusskurs vom Vortag:
$4.26
Offen:
$4.16
24-Stunden-Volumen:
86,477
Relative Volume:
0.60
Marktkapitalisierung:
$45.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.09M
KGV:
-2.3792
EPS:
-1.78
Netto-Cashflow:
$-17.24M
1W Leistung:
+6.14%
1M Leistung:
+36.17%
6M Leistung:
-21.57%
1J Leistung:
-6.72%
1-Tages-Spanne:
Value
$4.1001
$4.34
1-Wochen-Bereich:
Value
$3.55
$4.41
52-Wochen-Spanne:
Value
$2.55
$6.118

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
Firmenname
Lantern Pharma Inc
Name
Telefon
972-277-1136
Name
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Name
Mitarbeiter
24
Name
Twitter
@lanternpharma
Name
Nächster Verdiensttermin
2025-03-21
Name
Neueste SEC-Einreichungen
Name
LTRN's Discussions on Twitter

Vergleichen Sie LTRN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LTRN
Lantern Pharma Inc
4.235 45.94M 0 -19.09M -17.24M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-10-07 Eingeleitet H.C. Wainwright Buy

Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten

pulisher
02:18 AM

Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN

02:18 AM
pulisher
Jul 25, 2025

What analysts say about Lantern Pharma Inc. stockRapid growth opportunities - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bellingham Herald

Jul 25, 2025
pulisher
Jul 25, 2025

Is Lantern Pharma Inc. a good long term investmentFree Stock Market Real-Time Monitoring - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Will Lantern Pharma Inc. stock benefit from interest rate changesExceptional gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

How Lantern Pharma Inc. stock performs during market volatilityBalanced Risk Reward Portfolio - Newser

Jul 24, 2025
pulisher
Jul 24, 2025

Why Lantern Pharma Inc. stock is on top investor watchlistsOverwhelming financial success - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough stock performance - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Lantern Pharma Inc. stock priceTremendous gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma reports complete response in aggressive lymphoma patient - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

Jul 23, 2025
pulisher
Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284 - The Globe and Mail

Jul 22, 2025
pulisher
Jul 21, 2025

Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus

Jul 21, 2025
pulisher
Jul 17, 2025

Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest

Jul 17, 2025
pulisher
Jul 16, 2025

Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest

Jul 16, 2025
pulisher
Jul 15, 2025

Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser

Jul 15, 2025

Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Lantern Pharma Inc-Aktie (LTRN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Kreis Leslie W.
10% Owner
Jun 13 '25
Sale
3.09
40,000
123,600
49,957
Fletcher Aaron G.L.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Fletcher Aaron G.L.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Fletcher Aaron G.L.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Kreis Leslie W.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Kreis Leslie W.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Kreis Leslie W.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Fletcher Aaron G.L.
10% Owner
May 27 '25
Sale
3.05
21,037
64,163
56,467
Fletcher Aaron G.L.
10% Owner
May 29 '25
Sale
3.03
20,200
61,206
54,792
Fletcher Aaron G.L.
10% Owner
May 28 '25
Sale
2.87
15,000
43,050
55,753
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):